Table 1 Clinical and pathological information for 27 adenocarcinomas in the study
Tissueid | Age | Sex | Stage | Cell* | Diff# | Grade+ | Status | TTLF |
|---|---|---|---|---|---|---|---|---|
Lu1031 | 57 | Female | IA | AD | Well | II | 0 | 8.59 |
Lu1050 | 58 | Male | IB | AD | Well | II | 0 | 7.54 |
Lu1068 | 57 | Female | IB | AD | Mod | III | 1 | 3.28 |
Lu106 | 63 | Male | IB | AD | Well | II | 0 | 11.96 |
Lu113 | 89 | Female | IA | AD | Well | II | 1 | 5.68 |
Lu1182 | 61 | Female | IA | BAC | Well | II | 0 | 8.24 |
Lu1321 | 68 | Female | IB | AD | Well | II | 0 | 6.75 |
Lu1377 | 64 | Female | IA | AD | Well | II | 0 | 0.36 |
Lu1405 | 54 | Female | IB | AD | Mod | III | 0 | 8.03 |
Lu1450 | 74 | Female | IB | AD | Well | II | 0 | 8.08 |
Lu1479 | 64 | Female | IA | AD | Well | II | 0 | 8.08 |
Lu1518 | 55 | Female | IB | AD | Mod | III | 0 | 8.01 |
Lu1606 | 88 | Female | IA | AD | Well | II | 0 | 6.75 |
Lu1659 | 71 | Female | IA | AD | Well | II | 1 | 4.09 |
Lu1682 | 74 | Female | IA | AD | Well | II | 1 | 3.60 |
Lu1790 | 73 | Female | IB | AD | Well | II | 0 | 6.20 |
Lu1821 | 32 | Male | IB | AD | Mod | III | 0 | 6.47 |
Lu1848 | 46 | Female | IB | AD | Well | II | 0 | 5.29 |
Lu1942 | 70 | Male | IB | AD | Mod | III | 1 | 1.38 |
Lu1943 | 82 | Female | IB | AD | Well | II | 1 | 5.99 |
Lu2029 | 58 | Female | IB | AD | Well | II | 0 | 6.46 |
Lu2040 | 79 | Female | IB | AD | Mod | III | 0 | 0.78 |
Lu2368 | 58 | Female | IB | AD | Mod | III | 1 | 2.98 |
Lu2499 | 74 | Female | IB | BAC | Well | I | 0 | 5.03 |
Lu2502 | 77 | Female | IA | BAC | Well | II | 0 | 5.13 |
Lu346 | 67 | Female | IA | AD | Well | II | 0 | 5.08 |
Lu587 | 72 | Female | IB | BAC | Well | I | 0 | 5.85 |